Advancing discoveries to beat cancer
CRT develops and commercialises exciting new discoveries in cancer research. We’re the meeting point between academia and industry. Our deep understanding of both perspectives enables us to translate promising research into commercial propositions to deliver patient benefit and commercial value that will support further cancer research.
Exclusive rights to £300m of cancer research per year
Our marketed drugs include Temodal, Zytiga and Erivedge. What’s next?
We speak your language
CRT translates academic research into industry propositions.
£14m in industry funding leveraged last year
If a project looks promising, we’ll find a way to move it forward.
Realising clinical and commercial potential
We’re driven to achieve maximum patient benefit and market value.
Many projects, one focus: cancer
Our specialism means we’re more experienced, more knowledgeable and better connected.
CRT's in-house drug discovery unit, CRT Discovery Laboratories, translates cutting edge science into innovative new therapies for cancer patients.
With exclusive rights to more than £300m of world-class cancer research a year, we’re the gateway to much of the high quality oncology research happening in the UK today.
Do you have an idea or a discovery with commercial potential? Are you interested in working with industry? Our team can help develop the most promising projects.
| Start Date | Event |
|---|---|
| 16 April 2016 | AACR Annual Meeting 2016 |
| 03 April 2016 | Bio-Europe Spring 2016 |
| 14 February 2016 | AUTM 2016 Annual Meeting |
| 27 January 2016 | Accelerator Structural Biology Conference 2016 |
| 05 November 2015 | AACR-NCI-EORTC 2015 |
Pioneering Research 2014/15 – Cancer Research UK's annual research publication
Pioneering Research features some of the inspiring stories from across the Cancer Research UK community.
We've established major partnerships with research institutions, pharmas and biotechs of all sizes.
